A study of CCND1 with epithelial ovarian cancer cell proliferation and apoptosis.
Ovarian cancer is a gynecological malignancy with high mortality rates all over the world. Markers for diagnosis, prognosis and therapy are urgently required to improve the mortality rates. As a key proto-oncogene, CCND1 is known to be amplified in many different carcinomas, including breast cancer, esophageal cancer, bladder cancer, endometrial cancer and ovarian cancer, etc. CCND1 plays an important role in cancer development and progression. However, its function and mechanism have not been completely elucidated in ovarian cancer.



In the present study, we use cisplatin in vitro to inhibit the cell proliferation and promote cell apoptosis in epithelial ovarian cancer cell line SKOV-3. CCND1 expression, cell proliferation and cell cycle analysis were carried out by real-time PCR, CCK-8 and flow cytometry respectively.



Our results demonstrated that cisplatin could inhibit the expression of CCND1 in human epithelial ovarian cancer cell line, which is related to the decreased cell proliferation and increased cell apoptosis.



This study demonstrated that CCND1 is a potential therapeutic target for epithelial ovarian cancer treatment.
Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, China. pl_sci@163.com.
J
J
Dai
R-J
RJ
Wei
R
R
Li
J-B
JB
Feng
Y-L
YL
Yu
P-S
PS
Liu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D000077216:Carcinoma, Ovarian Epithelial; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002945:Cisplatin / Q000627:therapeutic use; D019938:Cyclin D1; D005260:Female; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial; D010051:Ovarian Neoplasms; D000090063:Proto-Oncogene Mas
D000970:Antineoplastic Agents; C530104:CCND1 protein, human; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D019938:Cyclin D1; D002945:Cisplatin